Drugs / RP2
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04336241 | Oct 2019 → Oct 2026 expected | cancer | Replimune, Inc. | Active not recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07862530 | Dec 2026 → Feb 2028 expected | cutaneous melanoma | Yana Najjar | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07059611 | Sep 2026 → Nov 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06623110 | Jan 2025 → Jan 2027 expected | precancerous condition | Glenn J. Hanna | Recruiting | No outcome recorded |
| Phase 2 | NCT05733598 | Aug 2024 → Dec 2027 expected | biliary tract cancer, hepatocellular carcinoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05733611 | Jun 2023 → Aug 2025 | colorectal cancer | Replimune, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06581406 | Dec 2024 → Jan 2030 expected | uveal melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-06-03 | Replimune, Inc. | Results Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting replimune.com ↗
RP2 demonstrated an acceptable benefit risk profile and meaningful antitumor activity in patients with uveal melanoma from the ongoing RP2 Phase 1 trial |
| 2022-12-07 | Replimune, Inc. | Results Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update replimune.com ↗
The Company also provided new data from the ongoing Phase 1 clinical trials evaluating RP2 and RP3, as well as a detailed overview of its RP2/3 Phase 2 development plans. |
| 2021-06-03 | Replimune, Inc. | Results Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1 replimune.com ↗
today announced updated interim data from the Phase 2 skin cancer cohorts combining RP1 (vusolimogene oderparepvec) with Opdivo®* (nivolumab) and data from RP2 alone and in combination with Opdivo that continues to provide strong support for development in its lead indications. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07862530 ↗ |
| Known as | vusolimogene oderparepvec | “RP2 (vusolimogene oderparepvec) RP2 will be injected directly into the tumor every 2 weeks for three doses before surgery.” NCT07862530 ↗ |
| Action | Deplete | “changed to grow in and destroy cancer cells” NCT06623110 ↗ |
| Modality | Other / unclassified | “RP2 (Oncolytic virus)” NCT06581406 ↗ |
| Route | Other | “Patients will receive RP2 intratumorally every 2 weeks (Q2W) for 4 doses, then every 3 weeks (Q3W) for 4 doses combined with atezolizumab plus bevacizumab.” NCT05733598 ↗ |